Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03633721 · ClinicalTrials.gov registry record · Phase 2

Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women

A Phase 2 study, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target

NCT03633721 is a Phase 2 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 25 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03633721, a Phase 2 study, has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target

Study Summary

The purpose of this study is to try to understand and explain why HIV-infected and uninfected women who use cannabis (marijuana) currently, or have used cannabis in the past, have higher risk of having experienced a fall in our earlier analyses in WIHS. This study will compare what happens when women are given cannabis compared with placebo, on measures of mobility, including walking speed under walking conditions that vary in terms of difficulty; for example normal walking and walking while reciting alternate letters of the alphabet, as well as measures of balance and cognition (for example attention, memory).

Interventions

  • OTHER Placebo
  • DRUG Cannabis

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2020-10-23
Est. Completion 2022-05-31
Phase Phase 2

Sponsor

Albert Einstein College of Medicine

175 total trials

What the Registry Record Tells You About NCT03633721

The ClinicalTrials.gov registry entry for NCT03633721 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03633721 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03633721 about?

NCT03633721 is a clinical study titled "Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women". The purpose of this study is to try to understand and explain why HIV-infected and uninfected women who use cannabis (marijuana) currently, or have used cannabis in the past, have higher risk of having experienced a fall in our earlier analyses in WIHS. This study will compare what happens when wome...

What is the current status of trial NCT03633721?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-10-23. Estimated completion is 2022-05-31.

What interventions are being tested in trial NCT03633721?

The interventions under investigation include: Placebo (OTHER), Cannabis (DRUG).

Who is sponsoring clinical trial NCT03633721?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.